文献速递胸部肿瘤放疗

肺癌放射治疗期间与急性食管炎相关的因素

Factors associated with acute esophagitis during radiation therapy for lung cancer.
PubMed 文献 · Radiother Oncol · 2024-05-28

这项前瞻性队列研究纳入2012至2022年全州联盟内接受根治性放疗±化疗的II-III期非小细胞肺癌患者1760例,采用logistic回归分析剂量学与临床因素与急性食管炎风险的关系。结果显示体能状态、食管平均剂量和D2cc与2级及以上和3级及以上食管炎显著相关,同步化疗与2级及以上食管炎相关但与3级及以上无关,并建立了预测50% 2级和3% 3级食管炎风险的模型。

要点

  • 1760例患者中急性2级及以上和3级及以上食管炎发生率分别为48.4%和2.2%。
  • 体能状态、食管平均剂量和D2cc与2级及以上及3级及以上食管炎显著相关。
  • 同步化疗与2级及以上食管炎相关,但与3级及以上食管炎无关。

核心结论

  • 体能状态、同步化疗、食管平均剂量和D2cc与根治性治疗非小细胞肺癌期间的急性食管炎相关。
  • 定量考虑这些因素的模型有助于个体化放疗计划。

研究设计与样本

  • 前瞻性收集2012至2022年全州联盟内接受根治性放疗±化疗的II-III期非小细胞肺癌患者的人口学、剂量学和急性毒性数据。
  • 采用logistic回归模型分析剂量学和临床协变量与2级及以上和3级及以上食管炎风险的关系。
  • 拟合多变量回归模型预测50%的2级食管炎风险和3%的3级食管炎风险。

主要发现

  • 1760例患者中,84.2%为III期疾病,85.3%接受同步化疗,79.2%的患者ECOG体能状态≤1。
  • 急性2级及以上和3级及以上食管炎的总发生率分别为48.4%和2.2%。
  • 多变量分析中,体能状态、食管平均剂量(MED)和接受最高剂量的2 cc食管的的最小剂量(D2cc)与2级及以上和3级及以上食管炎显著相关。
  • 同步化疗与2级及以上食管炎相关,但与3级及以上食管炎无关。

关键数值与推荐

  • 在所有患者中,MED为29 Gy和D2cc为61 Gy对应于3%的急性3级及以上食管炎风险。
  • 在接受化疗的患者中,MED为22 Gy和D2cc为50 Gy对应于50%的急性2级及以上食管炎风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Limiting acute esophagitis remains a clinical challenge during the treatment of locally advanced non-small cell lung cancer (NSCLC). METHODS: Demographic, dosimetric, and acute toxicity data were prospectively collected for patients undergoing definitive radiation therapy +/- chemotherapy for stage II-III NSCLC from 2012 to 2022 across a statewide consortium. Logistic regression models were used to characterize the risk of grade 2 + and 3 + esophagitis as a function of dosimetric and clinical covariates. Multivariate regression models were fitted to predict the 50 % risk of grade 2 esophagitis and 3 % risk of grade 3 esophagitis. RESULTS: Of 1760 patients, 84.2 % had stage III disease and 85.3 % received concurrent chemotherapy. 79.2 % of patients had an ECOG performance status ≤ 1. Overall rates of acute grade 2 + and 3 + esophagitis were 48.4 % and 2.2 %, respectively. On multivariate analyses, performance status, mean esophageal dose (MED) and minimum dose to the 2 cc of esophagus receiving the highest dose (D2cc) were significantly associated with grade 2 + and 3 + esophagitis. Concurrent chemotherapy was associated with grade 2 + but not grade 3 + esophagitis. For all patients, MED of 29 Gy and D2cc of 61 Gy corresponded to a 3 % risk of acute grade 3 + esophagitis. For patients receiving chemotherapy, MED of 22 Gy and D2cc of 50 Gy corresponded to a 50 % risk of acute grade 2 + esophagitis. CONCLUSIONS: Performance status, concurrent chemotherapy, MED and D2cc are associated with acute esophagitis during definitive treatment of NSCLC. Models that quantitatively account for these factors can be useful in individualizing radiation plans.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Herr DJ, Yin H, Bergsma D, et al. Factors associated with acute esophagitis during radiation therapy for lung cancer. Radiother Oncol. 2024. PMID: 38815695. doi:10.1016/j.radonc.2024.110349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。